Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ASH 2022 | Immunity of patients with multiple myeloma after vaccination against COVID-19

Evelyn Ullrich • 5 Dec 2022
ASH 2022
Multiple Myeloma

Evelyn Ullrich, MD, PhD, Goethe University Frankfurt, Frankfurt, Germany, reports the results of a study that used a comprehensive immune phenotyping framework to assess the immune responses of patients with multiple myeloma to SARS-CoV-2 vaccination. Multiple myeloma is associated with humoral and cellular immunosuppression, making patients more susceptible to severe COVID-19 infection. Analysis of the adaptive and innate immune cell compartments of patients with multiple myeloma revealed that specific cytokine-responsive NK cell and T cell populations appeared overrepresented in patients with successful vaccination responses, as well as a similar overrepresentation of these immune cells after breakthrough infections. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

BMS: Honoraria; Phialogics: Honoraria.

More from Evelyn Ullrich

The CAR FACTORY network: developing genetically optimized CAR-T and CAR-NK cellular therapies 2:06
The CAR FACTORY network: developing genetically optimized CAR-T and CAR-NK cellular therapies
Evelyn Ullrich • 11 Apr 2025
Advances in gene engineering technologies for NK cell-based immunotherapy 2:08
Advances in gene engineering technologies for NK cell-based immunotherapy
Evelyn Ullrich • 24 Apr 2023
Using CRISPR/Cas9 gene editing to generate NKG2A-knockout CD33-CAR-NK cells for the treatment of AML 3:09
Using CRISPR/Cas9 gene editing to generate NKG2A-knockout CD33-CAR-NK cells for the treatment of AML
Evelyn Ullrich • 5 Dec 2022
An insight into the use of CAR-NKs for the treatment of AML 4:20
An insight into the use of CAR-NKs for the treatment of AML
Evelyn Ullrich • 15 Mar 2022

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals